0 49

Cited 0 times in

Glioblastomas harboring gene fusions detected by next-generation sequencing

Authors
 Ha Young Woo  ;  Kiyong Na  ;  Jihwan Yoo  ;  Jong Hee Chang  ;  Young Nyun Park  ;  Hyo Sup Shim  ;  Se Hoon Kim 
Citation
 BRAIN TUMOR PATHOLOGY, Vol.37(4) : 136-144, 2020-10 
Journal Title
 BRAIN TUMOR PATHOLOGY 
ISSN
 1433-7398 
Issue Date
2020-10
MeSH
Aged ; Aged, 80 and over ; Biomarkers, Tumor / genetics ; Brain Neoplasms / genetics* ; Brain Neoplasms / mortality ; Brain Neoplasms / pathology ; Cytoskeletal Proteins / genetics ; Female ; Gene Fusion / genetics* ; Genetic Association Studies* ; Glioblastoma / genetics* ; Glioblastoma / mortality ; Glioblastoma / pathology ; Glioma / genetics* ; Glioma / mortality ; Glioma / pathology ; High-Throughput Nucleotide Sequencing* ; Humans ; Isocitrate Dehydrogenase / genetics ; Male ; Middle Aged ; Prognosis ; Proto-Oncogene Proteins c-met / genetics* ; Proto-Oncogene Proteins c-ret / genetics ; Receptor-Like Protein Tyrosine Phosphatases, Class 5 / genetics* ; Survival Rate
Keywords
Fusion ; Glioblastoma ; Glioma ; MET ; Next-generation sequencing
Abstract
Oncogenic gene fusions have been reported in diffuse gliomas and may serve as potential therapeutic targets. Here, using next-generation sequencing analysis (Illumina TruSight Tumor 170 panel), we analyzed a total of 356 diffuse gliomas collected from 2017 to 2019 to evaluate clinical, pathological, and genetic features of gene fusion. We found 53 cases of glioblastomas harboring the following oncogenic gene fusions: MET (n = 18), EGFR (n = 14), FGFR (n = 12), NTRK (n = 5), RET (n = 2), AKT3 (n = 1), and PDGFRA fusions (n = 1). Gene fusions were consistently observed in both IDH-wildtype and IDH-mutant glioblastomas (8.8% and 9.4%, p = 1.000). PTPRZ1-MET fusion was the only fusion that genetically resembled secondary glioblastomas (i.e., high frequency of IDH mutation, ATRX loss, TP53 mutation, and absence of EGFR amplification), whereas other gene fusion types were similar to primary glioblastomas (i.e., high frequency of IDH-wildtype, TERT mutation, EGFR amplification, and PTEN mutation). In IDH-wildtype glioblastoma patients, multivariable analysis revealed that the PTPRZ1-MET fusion was associated with poor progression-free survival (HR [95% CI]: 5.42 (1.72-17.05), p = 0.004). Additionally, we described two novel cases of CCDC6-RET fusion in glioma. Collectively, our findings indicate that targetable gene fusions are associated with aggressive biological behavior and can aid the clinical treatment strategy for glioma patients.
Full Text
https://link.springer.com/article/10.1007/s10014-020-00377-9
DOI
10.1007/s10014-020-00377-9
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Park, Young Nyun(박영년) ORCID logo https://orcid.org/0000-0003-0357-7967
Shim, Hyo Sup(심효섭) ORCID logo https://orcid.org/0000-0002-5718-3624
Woo, Ha Young(우하영) ORCID logo https://orcid.org/0000-0002-3078-6484
Yoo, Jihwan(유지환)
Chang, Jong Hee(장종희) ORCID logo https://orcid.org/0000-0003-1509-9800
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180094
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links